A systematic approach to reduce intraocular pressure for the treatment of glaucoma.

Glaucoma is the leading cause of irreversible blindness due to increased intraocular pressure (IOP) in the eye. We have developed a novel treatment option for glaucoma based on a real-time IOP-dependent nitric oxide synthase (NOS) and packed in a therapeutic contact lens to reduce the IOP. First, 1.6 nmole nitric oxide was produced from the genetic chassis, which was optimized for isopropyl ß-d-1-thiogalactopyranoside (IPTG) induction in a T7 expression system. For biosafety concerns to human being, the csgAD genes responsible for curli biofilm formation in Escherichia coli were co-expressed with NOS in the designated NOSAD strain to strengthen the adherence of cells to the contact lens, thereby preventing the contamination into the eyes. Moreover, NOSAD is a diaminopimelic acid (DAP) auxotrophic strain, which cannot survive without supplementation of DAP and reached the critical consideration of biosafety to the environment. We also demonstrated that the nitric oxide diffusion was 3.6-times enhanced from penetration into the aqueous humor of porcine eyes. The deformation ratio of the contact lens was correlated to the change of IOP by using a digital image correlation (DIC) system in a porcine eye model. The novel systematic approach provides an alternative treatment for glaucoma patients in the future.

Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics.

BACKGROUND: Despite the advancement in the fields of medical science and molecular biology, cancer is still the leading cause of death worldwide. Chemotherapy is a choice for treatment; however, the acquisition of chemoresistance is a major impediment for cancer management. Many mechanisms have been postulated regarding the acquisition of chemo-resistance in breast cancer and the impact on cellular signalling and the induction of apoptosis in tumour cells. The mechanism of the apoptotic mutation ofp53 and bcl-2 proteins is commonly associated with increased resistance to apoptosis and, therein, to chemotherapy. OBJECTIVES: The current study was aimed to investigate A172 and MDA-MB-231 cancer cells'sensitivity against chemotherapeutic drugs, including cisplatin, doxorubicin, and paclitaxel with different doses. Moreover, it estimates resistance of cancer cells by evaluating Nitric Oxide Synthase (NOS) expression and evaluate its correlation with the expression profile proteins of the apoptosis regulating Bcl-2 family. METHODS: Dose-dependent sensitivity to cisplatin, doxorubicin or paclitaxel was evaluated on spheroid cultured A172 and MDA-MB-231 cells lines, was measured by time-lapse microscopy over a 72h period. Expressions of two Nitric Oxide (NO) synthases isoforms (iNOS, eNOS), anti-apoptotic (Bcl-2, phospho-Bcl-2, Mcl-1, and Bcl-xL) and proapoptotic (BID, Bim, Bok, Bad, Puma, and Bax) were evaluated by Western blot. The effect of NO modulation on antiand pro-apoptotic molecule expression was also studied using Western blot. RESULTS: A172 cells show more resistance to chemotherapy drugs than MDA-MB-231 cancer cells, therefore, they need higher doses for apoptosis. Resistance of gliomas might be returned to higher significant expression of endothelial eNOS expression. It was clear that there is not a significant effect of NO modulation on the expression of pro- andantiapoptotic proteins on both cell lines. CONCLUSION: The present work provides a putative mechanism for the acquisition of drug resistance in breast cancer and glioma, which might be significant for clinical outcomes.

The Effects of the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin, Cannabinoid Agonist WIN 55,212-2, and Nitric Oxide Synthase Inhibitor Nω-Nitro-L-Arginine Methyl Ester Hydrochloride on the Serotonin and Dry Skin-Induced Itch.

INTRODUCTION: In many types of itch, the interaction between immune system cells, keratinocytes, and sensory nerves involved in the transmission of itch is quite complex. Especially for patients with chronic itching, current treatments are insufficient, and their quality of life deteriorates significantly. OBJECTIVE: In this study, we aimed to investigate the role of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), cannabinoid agonist WIN 55,212-2, and nitric oxide (NO) synthase inhibitor Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) in pruritus. METHODS: We created a serotonin (5-HT)-induced (50 µg/µL/mouse, i.d.) acute and acetone-ether-water (AEW)-induced chronic itching models. 17-AAG (1, 3, and 5 mg/kg, intraperitoneally [i.p.]), WIN 55,212-2 (1 mg/kg, i.p.), and L-NAME (1 mg/kg, i.p.) were applied to Balb/c mice. RESULTS: We found that 17-AAG suppressed the scratches of mice, depending on the dose. The itch behavior was reduced by WIN 55,212-2, but L-NAME showed no antipruritic effect at the administered dose. The combined application of these agents in both pruritus models showed synergism in terms of the antipruritic effect. Our results showed that NO did not play a role in the antipruritic effect of WIN 55,212-2 and 17-AAG. Increased plasma IgE levels with AEW treatment decreased with the administration of 17-AAG (5 mg/kg, i.p.) and WIN 55,212-2. CONCLUSION: These results demonstrate that Hsp90 may play a role in the peripheral pathway of pruritus, and cannabinoid agonists and Hsp90 inhibitors can be used together in the treatment of pruritus.

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.

The inducible nitric oxide signaling (iNOS) pathway is associated with poor prognosis in triple-negative breast cancer (TNBC). Prior studies using in vivo models showed that inhibition of the iNOS signaling pathway using the pan-NOS inhibitor NG-monomethyl-l-arginine (L-NMMA) reduced tumor growth and enhanced survival in patients with TNBC. Here, we report a first-in-class phase 1/2 trial of L-NMMA combined with taxane for treating patients with chemorefractory, locally advanced breast cancer (LABC) or metastatic TNBC. We also examined immune cell correlates of chemotherapy response. 35 patients with metastatic TNBC were recruited: 15 in the phase 1 trial and 24 in the phase 2 trial (including 4 recommended phase 2 dose patients from the phase 1 trial). The overall response rate was 45.8% (11 of 24): 81.8% (9 of 11) for patients with LABC and 15.4% (2 of 13) for patients with metastatic TNBC. Among the patients with LABC, three patients had a pathological complete response at surgery (27.3%). Grade ≥3 toxicity was noted in 21% of patients; however, no adverse events were attributed to L-NMMA. Immune cells analyzed by CyTOF indicated that chemotherapy nonresponders showed greater expression of markers associated with M2 macrophage polarization and increased concentrations of circulating IL-6 and IL-10 cytokines. In contrast, chemotherapy responders showed an increase in CD15+ neutrophils in blood, as well as a decrease in arginase (a marker of protumor N2 neutrophils) in tumor biopsies obtained at the end of treatment. L-NMMA combined with taxane warrants further investigation in larger clinical studies of patients with breast cancer.

Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells.

INTRODUCTION: Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment. The existing kinase inhibitor antiglycolytic drugs (B-Raf serine/threonine kinase or BRAF inhibitors) are effective for a short time followed by a rapid onset of drug resistance. PRESENTATION OF CASE: Here, we show that a mitochondria-targeted analog of magnolol, Mito-magnolol (Mito-MGN), inhibits oxidative phosphorylation (OXPHOS) and proliferation of melanoma cells more potently than untargeted magnolol. Mito-MGN also inhibited tumor growth in murine melanoma xenografts. Mito-MGN decreased mitochondrial membrane potential and modulated energetic and mitophagy signaling proteins. DISCUSSION: Results indicate that Mito-MGN is significantly more potent than the FDA-approved OXPHOS inhibitor in inhibiting proliferation of melanoma cells. CONCLUSION: These findings have implications in the treatment of melanomas with enhanced OXPHOS status due to metabolic reprogramming or drug resistance.

Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease.

Alzheimer's disease (AD) is a common neurodegenerative disease characterized by progressive memory loss. Magnolol (MN), the main active ingredient of Magnolia officinalis, possesses anti-AD effects in several experimental models of AD. In this study, we aimed to explore whether MN could ameliorate the cognitive deficits in TgCRND8 transgenic mice and to elucidate its molecular mechanisms. Male TgCRND8 mice were orally administered with MN (20 and 40 mg/kg) daily for 4 consecutive months, followed by assessing the spatial learning and memory functions using the open-field, radial arm maze, and novel object recognition tests. The results demonstrated that MN (20 and 40 mg/kg) could markedly ameliorate the cognitive deficits in TgCRND8 mice. In addition, MN significantly increased the expression of postsynaptic density protein 93 (PSD93), PSD-95, synapsin-1, synaptotagmin-1, synaptophysin (SYN), and interleukin-10 (IL-10), while markedly reduced the protein levels of tumor necrosis factor alpha (TNF-α), IL-6, IL-1ß, Aß 40, and Aß 42, and modulated the amyloid precursor protein (APP) processing and phosphorylation. Immunofluorescence showed that MN significantly suppressed the activation of microglia (Iba-1) and astrocytes (GFAP) in the hippocampus and cerebral cortex of TgCRND8 mice. Mechanistic studies revealed that MN could significantly increase the ratios of p-GSK-3ß (Ser9)/GSK-3ß, p-Akt (Ser473)/Akt, and p-NF-κB p65/NF-κB p65. These findings indicate that MN exerted cognitive deficits improving effects via suppressing neuroinflammation, amyloid pathology, and synaptic dysfunction through regulating the PI3K/Akt/GSK-3ß and NF-κB pathways, suggesting that MN is a promising naturally occurring polyphenol worthy of further developing into a therapeutic agent for AD treatment.

Sapropterina para o tratamento da fenilcetonúria / Sapropterin for treatment of phenylketonuria

INTRODUÇÃO: A FNC por deficiência de fenilalanina hidroxilase (FAH) é uma doença de padrão de herança autossômico recessivo, sendo classificada em FNC clássica, FNC leve ou hiperfenilalaninemia (HFA) não-FNC. A fenilalanina (FAL) é um aminoácido essencial, metabolizado no fígado pela enzima FAH e convertida no aminoácido tirosina (TIR). A não conversão de FAL em TIR leva ao aumento dos níveis plasmáticos de FAL e redução dos níveis de TIR. A doença não tratada caracteriza­se por atraso do desenvolvimento neuropsicomotor, retardo mental e crises convulsivas. O principal tratamento consiste em dieta restrita em FAL e uso de fórmula metabólica rica em aminoácidos, vitaminas e minerais e isenta em FAL. Embora não sejam deficientes em tetrahidrobiopterina (BH4), aproximadamente 30% dos pacientes com deficiência de FAH respondem à administração de BH4 com aumento do metabolismo de FAL para TIR. Dicloridato de sapropterina é a forma sintética do BH4 e administrado por via oral. TECNOLOGIA: Dicloridrato de sapropterina (Kuvan®). PERGUNTA: O uso de dicloridrato de sapropterina, isolado ou associado à dieta e uso de fórmula metabólica é eficaz e seguro quando comparado ao uso de dieta e fórmula metabólica sem BH4 em pacientes com FNC? EVIDÊNCIAS CIENTÍFICAS: Foram incluídos 4 ensaios clínicos randomizados (ECR) e 8 ensaios clínicos abertos prospectivos. Os estudos, na sua grande maioria, incluíram pequeno número de pacientes dada a prevalência da FNC, os quais, possuíam idades (crianças, adolescentes e adultos) e manifestações fenotípicas (FCN clássica e leve) variáveis. Foram identificadas duas revisões sistemáticas. Entretanto, a que não apresentou meta-análise não foi considerada, pois priorizou-se relatar os dados dos estudos primários. Mesmo a segunda revisão sistemática com meta-análise incluiu somente 2 estudos e para a grande maioria dos desfechos considerados não foi possível estimar uma única medida de associação. Os 2 estudos dessa revisão sistemática também foram considerados individualmente no presente parecer. A maioria dos ensaios clínicos investigou prioritariamente o desfecho nível de FAL plasmática, com amostras compostas por adultos, adolescentes ou crianças. Tais estudos demonstraram que, em pacientes com FNC responsivos à sapropterina, o tratamento, na maioria das vezes em conjunto com a dieta, reduziu substancialmente a concentração plasmática de FAL, oferecendo, assim, um melhor controle dos níveis plasmáticos da mesma. Os ensaios clínicos que avaliaram o desfecho tolerância à FAL, em menor número, demonstraram um aumento dessa tolerância o suficiente para permitir uma dieta menos restritiva ou, em alguns casos, substitui-la (descontinuação da dietoterapia). Os principais eventos adversos descritos foram sintomas relacionados ao sistema nervoso (ex.: cefaleia, enxaqueca, dificuldade de concentração) e distúrbios gastrointestinais (vômito, diarreia, gastroenterite). De modo geral, os achados apontam para um perfil de segurança aceitável para doses que não ultrapassam valores de 20 mg/kg/dia, sendo avaliada na grande maioria dos estudos ainda por um curto espaço de tempo. Eventos adversos após mais de um ano de tratamento são menos estudados, ainda que alguns estudos tenham apresentado seguimentos longos, como 2 e 7 anos. Uma vez que a evidência disponível para os desfechos de benefício de maior relevância foi de qualidade moderada, existe recomendação fraca a favor da inclusão da sapropterina no SUS como tratamento complementar na FNC para pacientes responsivos à mesma. AVALIAÇÃO DE IMPACTO ORÇAMENTÁRIO: Foi elaborado um modelo de impacto orçamentário para estimar os possíveis gastos decorrentes da incorporação do dicloridrato de sapropterina para tratamento da FNC no SUS em um horizonte temporal de 5 anos (2019 até 2023). Levando em consideração o custo anual das intervenções e a projeção do número de pacientes por intervenção, a incorporação da sapropterina geraria um impacto orçamentário incremental de aproximadamente R$ 79,3 milhões em 2019 e R$ 299,7 milhões após 5 anos (2019 a 2023). A análise de sensibilidade univariada estimou que o impacto orçamentário incremental da incorporação do dicloridrato de sapropterina pode variar de aproximadamente R$ 66,4 a R$ 102,58 milhões no primeiro ano e de R$ 251 a R$ 388 milhões ao longo dos cinco anos após a incorporação no SUS. MONITORAMENTO DO HORIZONTE TECNOLÓGICO: Foi identificado um medicamento de substituição enzimática, Pegvaliase (PAL-PEG), em fase 3 de pesquisa clínica, com registro aprovado no FDA em 2018. RECOMENDAÇÃO INICIAL: Pelo exposto, a CONITEC em sua 69ª reunião ordinária, no dia 02 de agosto de 2018, recomendou a não incorporação no SUS da sapropterina para FNC. Considerou-se que não foram apresentadas novas e robustas evidências ou argumentos que respaldem a tecnologia. Além disso, os membros ressaltaram o alto custo da tecnologia frente à incerteza do benefício que ela representa. A matéria foi disponibilizada em consulta pública. CONSULTA PÚBLICA: A Consulta Pública nº 43/2018 foi realizada entre os dias 21/08/2018 a 10/09/2018. Foram recebidas 919 contribuições, sendo 63 (6,9%) pelo formulário para contribuições técnico-científicas e 856 (93,1%) pelo formulário para contribuições sobre experiência ou opinião de pacientes, familiares, amigos ou cuidadores de pacientes, profissionais de saúde ou pessoas interessadas no tema. Das 63 contribuições recebidas de cunho técnicocientífico, 42 (67%) discordaram totalmente, dezessete (27%) discordaram parcialmente, um (2%) concordou totalmente e três (5%) concordou parcialmente da recomendação preliminar da CONITEC. Das 856 contribuições, 30 (4%) e quatro (1%) concordaram totalmente e parcialmente com a recomendação preliminar da CONITEC, respectivamente. Do restante, 105 (12%) discordaram parcialmente e 717 (84%) discordaram totalmente da recomendação preliminar da CONITEC. Após apreciação das contribuições encaminhadas pela consulta pública o plenário recomendou a incorporação do dicloridrato de sapropterina para o tratamento de mulheres com fenilcetonúria, com teste de responsividade positivo ao medicamento, e que estejam no período pré-concepcional ou em período gestacional, mediante negociação de preço e conforme protocolo clínico e diretrizes terapêuticas do Ministério da Saúde. RECOMENDAÇÃO FINAL DA CONITEC: Os membros da CONITEC presentes na 72ª reunião ordinária, no dia 8 de novembro de 2018, deliberaram, por unanimidade, recomendar a incorporação no SUS do dicloridrato de sapropterina para o tratamento de mulheres com Fenilcetonúria, com teste de responsividade positivo ao medicamento, e que estejam no período pré-concepcional ou em período gestacional. Foi assinado aos 08 (oito) dias do mês de novembro de 2018 registro de deliberação n° 390/2018 pela incorporação do medicamento dicloridrato de sapropterina ao SUS. DECISÃO: Incorporar o dicloridrato de sapropterina no tratamento da fenilcetonúria mediante negociação de preço e conforme Protocolo Clínico e Diretrizes Terapêuticas do Ministério da Saúde, no âmbito do Sistema Único de Saúde - SUS. Dada pela Portaria nº 78, publicada no DOU nº 241, seção 1, página 77, em 17 de dezembro de 2018.

Protective Role of Myelocytic Nitric Oxide Synthases against Hypoxic Pulmonary Hypertension in Mice.

RATIONALE: Nitric oxide (NO), synthesized by NOSs (NO synthases), plays a role in the development of pulmonary hypertension (PH). However, the role of NO/NOSs in bone marrow (BM) cells in PH remains elusive. OBJECTIVES: To determine the role of NOSs in BM cells in PH. METHODS: Experiments were performed on 36 patients with idiopathic pulmonary fibrosis and on wild-type (WT), nNOS (neuronal NOS)-/-, iNOS (inducible NOS)-/-, eNOS (endothelial NOS)-/-, and n/i/eNOSs-/- mice. MEASUREMENTS AND MAIN RESULTS: In the patients, there was a significant correlation between higher pulmonary artery systolic pressure and lower nitrite plus nitrate levels in the BAL fluid. In the mice, hypoxia-induced PH deteriorated significantly in the n/i/eNOSs-/- genotype and, to a lesser extent, in the eNOS-/- genotype as compared with the WT genotype. In the n/i/eNOSs-/- genotype exposed to hypoxia, the number of circulating BM-derived vascular smooth muscle progenitor cells was significantly larger, and transplantation of green fluorescent protein-transgenic BM cells revealed the contribution of BM cells to pulmonary vascular remodeling. Importantly, n/i/eNOSs-/--BM transplantation significantly aggravated hypoxia-induced PH in the WT genotype, and WT-BM transplantation significantly ameliorated hypoxia-induced PH in the n/i/eNOSs-/- genotype. A total of 69 and 49 mRNAs related to immunity and inflammation, respectively, were significantly upregulated in the lungs of WT genotype mice transplanted with n/i/eNOSs-/--BM compared with those with WT-BM, suggesting the involvement of immune and inflammatory mechanisms in the exacerbation of hypoxia-induced PH caused by n/i/eNOSs-/--BM transplantation. CONCLUSIONS: These results demonstrate that myelocytic n/i/eNOSs play an important protective role in the pathogenesis of PH.

Neuroprotective activity of cannabinoid receptor-2 against oxidative stress and apoptosis in rat pups having experimentally-induced congenital hypothyroidism.

In this study, it was aimed to show the cannabinoid receptor-2 (CB2) role, which is a part of neuroprotective endocannabinoidal system, against increasing nitric oxide synthetase (iNOS, eNOS) levels and the apoptotic activity (caspase-3, caspase-9, and DNA in situ fragmentation) within the postnatal critical period in pups of pregnant rats with artificially induced maternal thyroid hormone (TH) deficiency. Each of the three groups established comprised one male and two female rats, and they were coupled. Their pups were used. In the first two groups, the mothers were treated with 0.025% MMI during the critical period of the pregnancy. In the third group, as the control group, the mothers and pups were not treated. Euthanasia was applied to the pups in Group I on Day 10, and to the pups in Groups II and III on Day 21. In the biochemical analyses, total T4 levels of both mothers and pups in Group I and II were found to be lower than those of the control group. Histopathologically, karyopyknosis in migrating neurons and demyelinization were observed in both groups. Caspase-3 and -9 expressions and TUNEL reactions showed parallelism to these findings. eNOS and iNOS activities were also increased in Groups I and II. CB2 receptor activity was observed in the fore and mid brain in Group I, and in the whole brain in Group II. In conclusion, apoptosis was triggered via oxidative stress in hypothyroid pups. Accordingly, neuroprotective activity of CB2 receptors were motivated spontaneously to resist to CNS lesions during the first 3 weeks of postnatal period. © 2017 Wiley Periodicals, Inc. Develop Neurobiol 77: 1334-1347, 2017.

Enhancing Nitric Oxide Bioavailability via Exogen Nitric Oxide Synthase and L-Arginine Attenuates Ischemia-Reperfusion-Induced Microcirculatory Alterations.

BACKGROUND: Nitric oxide (NO) is an important cytoprotective agent against ischemia and reperfusion injury (IRI). Enhancing NO bioavailability via exogen NO synthases (NOSs) and L-arginine promotes conversation to NO, circumventing the problem of nonfunctioning NOSs under hypoxic and acidic conditions. In this study, the authors evaluated the therapeutic efficacy of endothelial, inducible and neuronal NOS, and L-arginine on reperfusion-induced microcirculatory alterations and hemodynamic adverse effects in the microvasculature of skeletal muscle. METHODS: Vascular pedicle isolated rat cremaster model was used that underwent 2 hours of warm ischemia followed by 1 hour of reperfusion. At 30 minutes before ischemia, normal saline (control group with/without ischemia), endothelial-, inducible-, and neuronal NOSs (2 IE) and L-arginine (50 mg/kg BW) were administered systemically (IV). Ischemia-reperfusion-induced microcirculatory alterations were measured after 1 hour of reperfusion. Mean arterial blood pressure and heart frequency were measured throughout the experiment to determine hemodynamic adverse effects. RESULTS: The isoforms of NOSs and L-arginine attenuated ischemia-reperfusion-induced vasoconstriction, improved red blood cell velocity, capillary flow, and leukocyte adherence to the endothelium wall. Hemodynamics was stable throughout the experiment. CONCLUSIONS: Enhancing NO bioavailability via exogen application of NOSs and L-arginine significantly attenuated ischemia-reperfusion-induced microcirculatory alterations in the microvasculature of skeletal muscle. Significant hemodynamic adverse effects were not present, thus demonstrating this approach might be useful for therapeutic intervention. This "pharmacologic preconditioning" could be an easy and effective interventional strategy to uphold conversation of L-arginine to NO under ischemic conditions.

Sapropterin is safe and effective in patients less than 4-years-old with BH4-responsive phenylalanine hydrolase deficiency.

OBJECTIVE: To assess the safety and efficacy of tetrahydrobiopterin therapy with sapropterin to treat tetrahydrobiopterin (BH4)-responsive phenylalanine hydroxylase (PAH) deficiency in children aged <4 years compared with those aged ≥4 years. STUDY DESIGN: We analyzed a longitudinal follow-up study conducted in all patients with BH4-responsive PAH deficiency throughout Japan. At the end of 2011, 43 patients were receiving sapropterin, of whom 21 were aged <4 years at the initiation of treatment. The starting dose of sapropterin was ≥10 mg/kg/day in 11 of these 21 patients. The duration of follow-up was ≥4 years in 6 of those 11 patients; 3 of these 6 were followed for ≥10 years. Nine patients were receiving sapropterin monotherapy at the end of 2011. RESULTS: Serum phenylalanine level was maintained within the recommended optimal control range in all 21 patients who started sapropterin treatment before age 4 years. Only 1 nonserious adverse drug reaction occurred, an elevated alanine aminotransferase level in 1 patient. No significant abnormal behavior related to nerve disorders was reported. CONCLUSION: Sapropterin therapy initiated before age 4 years was effective in maintaining serum phenylalanine level within the favorable range and was safe in Japanese patients with BH4-responsive PAH deficiency.

L-N-iminoethyl-lysine after experimental brain trauma attenuates cellular proliferation and astrocyte differentiation.

BACKGROUND: The effects, and thereby possible benefit, of inhibiting nitric oxide synthases (NOS) after brain injury are not fully understood. Nitric oxide (NO) has both neuroprotective and damaging features, and its effect on the cellular proliferation and differentiation that occurs in response to traumatic brain injury (TBI) is largely unknown. This study was undertaken to investigate the effects of the selective inducible NOS-inhibitor, L-N-iminoethyl-lysine (L-NIL), on proliferating cell populations in rat brain areas with self-renewing capacity. METHODS: A brain contusion was produced using a weight-drop model in rats. Animals received treatment with L-NIL or saline, and were killed after 6 days. Brain sections were stained with a cell marker of proliferation, Ki67, to detect dividing cells in the hippocampus, perilesional zone and the subventricular zone (SVZ). RESULTS: A significant decrease of proliferating cells was seen in the SVZ bilaterally in L-NIL-treated animals compared to controls. Hippocampal proliferation showed a tendency to decrease in L-NIL-treated animals that did not reach statistical significance. Perilesional proliferation was equal in the treatment group and controls. The percentage of proliferating GFAP expressing cells was, however, lower in L-NIL-treated animals. The proliferating cell populations were predominantly immunoreactive for GFAP, while a smaller population was immunoreactive for Nestin. The inhibition of inducible NOS with L-NIL attenuated the level of cellular proliferation and influenced the differentiation of astrocytes at 6 days after experimental brain contusion. CONCLUSIONS: Our results confirmed that reactive glial cells dominated the proliferating cell population after TBI and suggested that NO-regulated mechanisms are relevant for post-traumatic cellular proliferation and differentiation, since NO inhibition decreased the number of proliferating cells in the SVZ and the proportion of proliferating cells expressing GFAP, a marker of glial proliferation.

Derivados de 4, 5-DIHIDRO-1H-PIRAZOL como inhibidores selectivos de nNOS: Síntesis y relaciones estructura-actividad / 4, 5-DIHYDRO-1H-PYRAZOLE as nNOS selective inhibitors: Synthesis and structure-activity relationship

INTRODUCCIÓN: La oxido nítrico sintasa (NOS) es la enzima que cataliza la biosíntesis de óxido nítrico (NO) a partir de L-arginina. 1 Hasta el momento, se han descubierto cuatro isoformas:2 nNOS, iNOS, eNOS y mtNOS. El NO es un biomensajero relacionado con importantes funciones fisiológicas. 3Sin embargo, se ha demostrado que una sobreproducción de NO por la nNOS está implicada en procesos neurodegenerativos. 4 Este hecho justifica la necesidad terapéutica de encontrar inhibidores selectivos de la nNOS que permitan luchar contra enfermedades tales como Alzheimer, Parkinson, esclerosis lateral amiotrófica y corea de Huntington. Nuestro grupo de investigación ha sintetizado y evaluado una serie de derivados kinurenínicos 5 1 y kinurenamínicos 6 2 como agentes neuroprotectores que resultaron desprovistos de actividad inhibitoria frente a la enzima kinurenina-3-hidroxilasa (KYN3OH), lo que demuestra que su actividad neuroprotectora se debe a la inhibición de la nNOS. OBJETIVO: Basándonos en estos antecedentes, hemos sintetizado y realizado la evaluación biológica in vitrofrente a las isoformas nNOS e iNOS de una serie de derivados de 4,5-dihidro-1H-pirazol con estructura general 3, con objeto de encontrar inhibidores selectivos de alguna de estas isoformas. METODOLOGÍA: Tomando como referencia los derivados kinurenínicos y kinurenamínicos, hemos sintetizado los análogos rígidos con un resto de 4,5-dihidro-1H-pirazol. Además de la restricción conformacional, se han llevado a cabo otras modificaciones, como la introducción de distintos sustituyentes en el anillo aromático y la modificación del grupo acilo en el anillo de pirazolina(AU)

CONCLUSIÓN /DISCUSIÓN: Todos los compuestos ensayados inhiben nNOS. La inhibición de iNOS es ínfima en la mayoría de los casos, por lo que se pueden considerar selectivos, y no hay inhibición de KYN3OH. Por consiguiente, el potencial neuroprotector de estos derivados se debe únicamente a la inhibición de nNOS(AU)

INTRODUCTION: Nitric Oxide Synthase (NOS) is the enzyme which catalyses the biosynthesis of Nitric Oxide (NO)from L-arginine 1. Four NOS isoforms have been described: 2 nNOS, iNOS, eNOS and mtNOS. NO is a biological messenger involved in several physiologic processes. 3 However, an over production of NO by nNOS produces neurotoxicity which has been associated with various neurological disorders 4.Therefore, it is necessary to found nNOS inhibitors to fight pathologies such as Alzheimer’s disease, Parkinson, amyotrophic lateral sclerosis and Huntington’s disease. In previous papers, our research group have described the synthesis of a series of kynurenine 5 1 and kynurenamine 6 2 derivatives as neuroprotective agents which are not active versus kynurenine-3-hydroxylase (KYN3OH). This fact demonstrates that their neuroprotective activity is only due to then NOS inhibition. 2 3 OBJECTIVE: Basing on these precedents, we have developed and evaluated in vivo, versus nNOS and iNOS, a series of 4,5-dihydro-1H-pyrazole derivatives with general structure 3 in order to find new selective compounds. METHODOLOGY: Taking kynurenine and kynurenamine derivatives as reference, we have synthesized rigid analogous with a ring of 4,5-dihydro-1H-pyrazole . Besides the conformacional restriction, other modification shave been carried out, as the introduction of different substituents in the aromatic ring and the modification of the acyl group in the pyrazoline ring . CONCLUSION /DISCUSION: All compounds inhibit nNOS. In most of cases, the inhibition of iNOS is negligible. Thus, they can be considered selective. On the other hand, there is no KYN3OH inhibition. Consequently, the neuroprotective potential of these derivatives is due only to the inhibition of nNOS(AU)

Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.

Pulmonary arterial hypertension (PAH) is a progressive and lethal disease that has a strong female predominance, often affecting the young. Current therapies are mostly vasodilator agents, and while mainly addressing the endothelial dysfunction that has been widely reported in this disease, they may be less effective in treating arterial remodeling. The lung pathology of PAH is characterized by medial hypertrophy and intimal hyperplasia of muscular arteries as well as plexiform lesions, that lead to a widespread narrowing or obliteration of the pulmonary arteriolar bed. However, the pathogenesis of the functional and structural abnormalities of the lung microcirculation in PAH is poorly understood. Perhaps the greatest advancement in the last decade has been the discovery of the "PAH gene," bone morphogenetic receptor 2 (Bmpr2), however how the loss-of-function mutations in Bmpr2 lead to PAH is unclear. The BMPR2 pathway has recently been shown to mediate survival signaling in endothelial cells (EC), and thus the reduced activity will favor endothelial apoptosis, likely increasing the susceptibility to endothelial injury in response to various environmental triggers. EC apoptosis has been implicated as an initiating event in experimental PAH, leading either directly to the degeneration of pre-capillary arterioles or to the selection of hyperproliferative, apoptosis-resistant ECs that may contribute to "angioproliferative" plexiform lesions. The idea that EC apoptosis may play a central role in the initiation and progression of PAH suggests that therapeutic strategies aimed at endothelial repair and regeneration of ECs may be uniquely effective in the treatment of this disease. Preclinical evaluation and validation on the use of endothelial progenitor cells (EPCs) for the prevention and reversal of experimental PAH is reviewed and the design of a "first in man" clinical trial to assess the safety and efficacy of a combined EPC and endothelial NO-synthase gene therapy for patients that are refractory to standard therapies is discussed.

Tetrahydrobiopterin in the prevention of hypertonia in hypoxic fetal brain.

OBJECTIVE: Tetrahydrobiopterin (BH(4)) deficiency is a cause of dystonia at birth. We hypothesized that BH(4) is a developmental factor determining vulnerability of the immature fetal brain to hypoxic-ischemic injury and subsequent motor deficits in newborns. METHODS: Pregnant rabbits were subjected to 40-minute uterine ischemia, and fetal brains were investigated for global and focal changes in BH(4). Newborn kits were assessed by neurobehavioral tests following vehicle and sepiapterin (BH(4) analog) treatment of dams. RESULTS: Naive fetal brains at 70% gestation (E22) were severely deficient for BH(4) compared with maternal and other fetal tissues. BH(4) concentration rapidly increased normally in the perinatal period, with the highest concentrations found in the thalamus compared with basal ganglia, frontal, occipital, hippocampus, and parietal cortex. Global sustained 40-minute hypoxia-ischemia depleted BH(4) in E22 thalamus and to a lesser extent in basal ganglia, but not in the frontal, occipital, and parietal regions. Maternal supplementation prior to hypoxia-ischemia with sepiapterin increased BH(4) in all brain regions and especially in the thalamus, but did not increase the intermediary metabolite, 7,8-BH(2). Sepiapterin treatment also reduced incidence of severe motor deficits and perinatal death following E22 hypoxia-ischemia. INTERPRETATION: We conclude that early developmental BH(4) deficiency plays a critical role in hypoxic-ischemic brain injury. Increasing brain BH(4) via maternal supplementation may be an effective strategy in preventing motor deficits from antenatal hypoxia-ischemia.

Targeting cardiac sympatho-vagal imbalance using gene transfer of nitric oxide synthase.

Heightened sympathetic excitation and diminished parasympathetic suppression of heart rate, cardiac contractility and vascular tone are all associated with cardiovascular diseases such as hypertension and ischemic heart disease. This phenotype often exists before these disease states have been established and is a strong correlate of mortality in the population. However, the causal role of the autonomic phenotype in the development and maintenance of hypertension and myocardial ischemia remains a subject of debate, as are the mechanisms responsible for regulating sympathovagal balance. Emerging evidence suggests oxidative stress and reactive oxygen species (such as nitric oxide (NO) and superoxide) play important roles in the modulation of autonomic balance, but so far the most important sites of action of these ubiquitous signaling molecules are unclear. In many cases, these mediators have opposing effects in separate tissues rendering conventional pharmacological approaches non-efficacious. Novel techniques have recently been used to augment these signaling pathways experimentally in a targeted fashion to central autonomic nuclei, cardiac neurons, and myocytes using gene transfer of NO synthase. This review article discusses these recent advances in the understanding of the roles of NO and its oxidative metabolites on autonomic imbalance in models of cardiovascular disease.

Gene therapy approaches to enhance bioreductive drug treatment.

Hypoxia, or a lack of oxygen, occurs in 50-60% of solid human tumours. Clinical studies have shown that the presence and extent of hypoxia in a tumour cannot be predicted by size or histopathological stage but it is predictive of a poor outcome following radiotherapy, chemotherapy and surgery. However, as a physiological feature of tumours, it can be exploited and researchers have developed many hypoxia-selective chemotherapies or bioreductive drugs that are in varying stages of clinical development. These agents are prodrugs that have two key requirements for their biological activation: they require the reductive environment of a hypoxic tumour cell and the appropriate complement of cellular reductase enzymes. To overcome tumour heterogeneity in reductase enzyme levels and enhance bioreductive drug metabolism a gene therapy strategy can be employed. We have reviewed this field and also present our own pre-clinical research using gene therapy to enhance bioreductive drug treatment for the treatment of cancer. We have specifically focused on studies enhancing lead clinical bioreductive drugs. We consider the metabolic requirements for their activation and we highlight the key in vivo studies supporting the future clinical development of hypoxia-targeted gene-directed enzyme prodrug therapy.

Anti-oxidant strategies.

Oxidative stress plays an important role in causing organ injury in the compromised fetus and neonate. Recent experimental research and clinical studies have clarified important pathways in the production of reactive oxygen and nitrogen species. Free radicals are involved in causing cerebral damage after perinatal hypoxia-ischemia affecting membrane lipids, proteins, and DNA. Anti-oxidant strategies can be used as add-on neuroprotective therapy after perinatal oxidative stress. Selective inhibitors of neuronal and inducible nitric oxide synthase, allopurinol, melatonin, and erythropoietin are among the first compounds that are ready for clinical trials.